4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
06 juin 2024 07h30 HE
|
4D Molecular Therapeutics, Inc.
Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up ...
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
04 juin 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Participate in Upcoming Investor Conferences
03 juin 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
30 mai 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024...
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
09 mai 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3...
4DMT to Participate in Upcoming Investor Conference
07 mai 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Announces Presentations at ARVO 2024 Annual Meeting
01 mai 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a...
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
28 mars 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of...
4DMT to Participate in Upcoming Investor Conferences
04 mars 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 févr. 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling...